SIGN UP
LOG IN
I
IMMP
Immutep
1.63
-0.05-2.98%After Hours: 1.700 +0.070 +4.29%16:30 04/25 EDT
OPEN/PREV CLOSE1.693/1.680
TODAY RANGE1.610-1.730
VOL60.69K
MARKET CAP238.04M
52 WEEK RANGE1.320-3.335
AVG VOL (3M)75.48K
% TURNOVER0.04%
TURNOVER--
P/E (TTM)-7.9668
% RANGE7.14%
EPS(TTM)-0.2046
P/E(FORWARD)-6.2428
P/B2.213
BVPS0.7367
DIVIDEND--
P/S16,300.00
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP238.02M
SHARES OUTSTANDING146.04M
NEXT EARNINGS07/29-08/04
FREE FLOAT146.02M
LOT SIZE1
EX-DIV DATE12/28/2016
News
Press Releases
Financial Reports
Profile
Seeking Alpha·03/31 15:50
Immutep: A Small Company With A Pipeline Resembling Big Pharma
TipRanks·03/07 02:05
Immutep Ltd (PRRUF) Receives a Buy from Canaccord Genuity
TipRanks·03/03 03:52
Immutep Reports Increased Revenue Amid Growing R&D Costs
Dow Jones·02/26 22:03
*Immutep Target Price Raised 5.0% to A$2.10/Share by Jefferies>IMM.AU
TipRanks·02/03 11:29
Immutep Advances to Phase III with Key Approvals and Promising Trial Results
TipRanks·01/31 13:12
Immutep promotes Christian Mueller to CDO, CMO Florian Vogl to depart
TipRanks·01/31 13:05
Immutep reports Q2 cash receipts from customers A$8,000
TipRanks·01/28 22:35
Immutep Ltd (PRRUF) Gets a Buy from Canaccord Genuity
Seeking Alpha·01/28 21:37
Immutep Limited: Continuing To Make The Case For Eftilagimod
TipRanks·01/22 13:11
Immutep announces patient enrollment completed for EFTISARC-NEO Phase II trial
Reuters·01/22 13:00
IMMUTEP LTD - DATA UPDATES FROM EFTISARC-NEO EXPECTED IN 2025
Same Industry
Name/Symbol
Change%
Price
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
② More than 40M Downloads Globally : data based on Webull Technologies Limited's internal statistics as of July 14, 2023.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
② More than 40M Downloads Globally : data based on Webull Technologies Limited's internal statistics as of July 14, 2023.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.